CD8A and cancer: The SARS-CoV-2-specific CD8+ T cell responses (CD69+ CD137+) were detected in 8 (38.1%) of 21 in CAD, 14 (38.9%) of 36 in hypertension, 16 (72.7%) of 22 in DM, 11 (61.1%) of 18 in CRD, 6 (66.7%) of 9 in cancer versus 34 (60.7%) of 56 in the health control (Supplementary Table 7).